Guardant Health’s (GH) Buy Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Guardant Health (NASDAQ:GH) in a research report report published on Monday,Benzinga reports. They currently have a $56.00 price target on the stock.

GH has been the subject of a number of other reports. Canaccord Genuity Group lifted their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday. Sanford C. Bernstein dropped their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. The Goldman Sachs Group upped their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Raymond James reissued an “outperform” rating and set a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Nineteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $48.21.

Guardant Health Stock Performance

GH stock opened at $43.19 on Monday. Guardant Health has a one year low of $15.81 and a one year high of $50.89. The firm has a market cap of $5.33 billion, a PE ratio of -12.13 and a beta of 1.32. The firm’s 50 day moving average price is $40.65 and its 200-day moving average price is $31.82.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Equities research analysts predict that Guardant Health will post -2.9 EPS for the current fiscal year.

Insider Activity

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 2,768 shares of company stock worth $98,798. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Guardant Health

Large investors have recently bought and sold shares of the business. Lord Abbett & CO. LLC purchased a new position in shares of Guardant Health in the 3rd quarter valued at approximately $15,624,000. Guyasuta Investment Advisors Inc. purchased a new position in Guardant Health in the 4th quarter valued at $206,000. Cerity Partners LLC increased its stake in Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after buying an additional 68,883 shares during the period. Geode Capital Management LLC raised its position in Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after buying an additional 29,686 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in shares of Guardant Health in the 4th quarter worth $377,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.